Summary
This multicentre international study developed and validated genomic biomarkers intended to identify bladder cancer patients likely to benefit from cisplatin-based neoadjuvant chemotherapy, supporting precision medicine approaches to treatment selection. The work examined molecular signatures across multiple patient cohorts to assess their predictive value in oncological care. Specific biomarker compositions and detailed performance metrics require consultation of the full publication.
UK applicability
If validated, such genomic biomarkers could inform treatment selection in UK bladder cancer services; however, applicability depends on assay accessibility, cost, and integration into National Health Service pathways. The study's international cohorts may or may not reflect UK patient demographics and healthcare contexts.
Key measures
Genomic biomarker predictive performance (sensitivity, specificity, and/or area under receiver operating characteristic curve as suggested by typical oncology biomarker validation); patient response to cisplatin-based neoadjuvant chemotherapy
Outcomes reported
The study developed and validated genomic biomarkers to predict which bladder cancer patients would respond favourably to cisplatin-based neoadjuvant chemotherapy. Performance metrics of these predictive signatures were assessed across multiple international patient cohorts.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.